Home
ASND

ASND

Ascendis Pharma A/S

as of 11-28-2025 12:30pm EST

$212.73

+$2.72

+1.30%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Chart Type:

Time Range:

Founded:	2006	Country:	Denmark
Employees:	N/A	City:	N/A
Market Cap:	12.2B	IPO Year:	2015
Target Price:	$256.27	AVG Volume (30 days):	571.7K
Analyst Decision:	Strong Buy	Number of Analysts:	15
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-4.54	EPS Growth:	N/A
52 Week Low/High:	$118.03 - $223.19	Next Earning Date:	11-12-2025
Revenue:	$758,592,045	Revenue Growth:	97.46%
Revenue Growth (this year):	104.98%	Revenue Growth (next year):	79.91%

AI-Powered ASND Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold

Model Accuracy: 66.00%

66.00%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full ASND Forecast & Prediction with Hourly Data

Compare ASND vs Leading Stocks

See how ASND stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free ASND Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "ASND Ascendis Pharma A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.